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Background: It is well known that axotomy in the neonatal period causes massive loss of motoneurons, which is
reflected in the reduction of the number of motor units and the alteration in muscle properties. This type of
neuronal death is attributed to the excessive activation of the ionotropic glutamate receptors (glutamate
excitotoxicity). In the present study we investigated the effect of the NMDA antagonist DAP5 [D-2-amino-5-
phosphonopentanoic acid] in systemic administration, on muscle properties and on behavioural aspects following
peripheral nerve injury.
Methods: Wistar rats were subjected to sciatic nerve crush on the second postnatal day. Four experimental groups
were included in this study: a) controls (injection of 0.9% NaCl solution) b) crush c) DAP5 treated and d) crush and
DAP5 treated. Animals were examined with isometric tension recordings of the fast extensor digitorum longus and
the slow soleus muscles, as well as with locomotor tests at four time points, at P14, P21, P28 and adulthood
(2 months).
Results: 1. Administration of DAP5 alone provoked no apparent adverse effects. 2. In all age groups, animals with
crush developed significantly less tension than the controls in both muscles and had a worse performance in
locomotor tests (p< 0.01). Crush animals injected with DAP5 were definitely improved as their tension recordings
and their locomotor behaviour were significantly improved compared to axotomized ones (p< 0.01). 3. The time
course of soleus contraction was not altered by axotomy and the muscle remained slow-contracting in all
developmental stages in all experimental groups. EDL, on the other hand, became slower after the crush (p< 0.05).
DAP5 administration restored the contraction velocity, even up to the level of control animals 4. Following crush,
EDL becomes fatigue resistant after P21 (p< 0.01). Soleus, on the other hand, becomes less fatigue resistant. DAP5
restored the profile in both muscles.
Conclusions: Our results confirm that contractile properties and locomotor behaviour of animals are severely
affected by axotomy, with a differential impact on fast contracting muscles. Administration of DAP5 reverses these
devastating effects, without any observable side-effects. This agent could possibly show a therapeutic potential in
other models of excitotoxic injury as well.* Correspondence: achatzisot@med.auth.gr
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Peripheral nerve injury during the critical period of
development imparts severe structural and functional
consequences on the muscles of the growing animal. It
has been well documented that axotomy in the early
postnatal period reduces the number of surviving
motoneurons in the ventral horn of the lumbar segments
and induces changes in the contractile properties of limb
muscles [1,2]. These consequences have been ascribed to
the critical dependency of the developing motoneurons
on their interaction with their target muscle [3,4], as well
as to their increased susceptibility to the excitotoxic
effects of glutamate [5,6].
Glutamate is the major excitatory neurotransmitter in
the CNS. Ionotropic receptors of glutamate (NMDA and
AMPA/kainate) have been identified throughout the
brain and the spinal cord. In case of overactivation ofTable 1 EDL tension recordings-comparisons
AGE
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Post-hoc multiple comparisons. The actual parameters are presented in the graphs.
a = 0.05.these receptors, the excessive Ca2+ influx into the cell
induces a cell death cascade, which comprises the
activation of proteases, lipases and other enzymes
leading to cell lysis [7]. As it has been shown by previous
studies [8-10], this is a time-dependent process, as
motoneurons are particularly vulnerable to excitotoxic
cell death, only during the first five days of postnatal life.
In the present study we performed sciatic nerve crush in
neonatal rats and we investigated the effect of the NMDA
antagonist DAP5 [D-2-amino-5-phosphonopentanoic
acid] in systemic administration, on muscle properties and
on behavioural aspects following injury. This agent has
been largely implemented for its antinociceptive action
[11-13], as well as for its effects on memory consolidation
and hippocampal rhythm [14,15]. In all these studies, the
above agent was either delivered intrathecally, or in






























*: different from control. #: different from crush. Level of significance was
Table 2 EDL tension recordings
EDL
AGE PROCEDURE ANOVA ON THE RANKS
CONTROL CRUSH DAP5 CRUSH-DAP5 P-VALUE
WEIGHT-INDEX P14 0.04 ± 0.01 0.02 ± 0.* 0.04 ± 0.01 0.03 ± 0.01 0.017
P21 0.05 ± 0.01 0.02 ± 0.* 0.04 ± 0.01 0.03 ± 0.# 0.002
P28 0.06 ± 0.01 0.02 ± 0.* 0.06 ± 0.01 0.04 ± 0.# 0.001
ADULT 0.08 ± 0.01 0.01 ± 0.* 0.09 ± 0.01 0.08 ± 0.01 0.003
TETANIC-10 (g) P14 6.59 ± 0.89 1.94 ± 0.16* 7.21 ± 1.21 6.79 ± 0.29 0.011
P21 9.96 ± 0.63 4.68 ± 0.79* 10.66 ± 1.37 9.39 ± 1.71 0.010
P28 17.4 ± 1.39 4.94 ± 0.26* 18.24 ± 0.53 15.05 ± 1.95# 0.002
ADULT 86.72 ± 3.55 6.05 ± 0.63* 87.42 ± 4.1 72.59 ± 2.85# 0.001
TETANIC-20 (g) P14 8.13 ± 1.3 2.5 ± 0.34* 8.06 ± 1.02 7.62 ± 0.46 0.012
P21 13.27 ± 1.52 6.04 ± 0.64* 12.51 ± 0.86 10.65 ± 1.54 0.003
P28 24.51 ± 1.19 5.6 ± 0.41* 24.45 ± 0.98 20.88 ± 1.68# 0.001
ADULT 117.45 ± 5.37 7.71 ± 0.96* 119.52 ± 4.78 105.08 ± 13.66 0.004
TETANIC-40 (g) P14 9.46 ± 1.64 3.3 ± 0.48* 9.79 ± 1.65 8.87 ± 0.46 0.011
P21 18.46 ± 1.06 8.15 ± 0.37* 17.53 ± 0.91 14.61 ± 1.44# 0.001
P28 37.92 ± 1.44 8.9 ± 0.58* 38.75 ± 1.66 31.48 ± 2.91# 0.001
ADULT 177.78 ± 14.95 13.22 ± 1.15* 179.26 ± 8.94 140.83 ± 10.29# 0.001
TETANIC-80 (g) P14 10.35 ± 1.78 3.91 ± 0.52* 10.63 ± 1.82 9.57 ± 0.32 0.012
P21 22.42 ± 1.22 10.87 ± 1.29* 21.36 ± 0.96 17.49 ± 1.94# 0.001
P28 49.95 ± 1.34 10.79 ± 0.97* 52.9 ± 1.06 41.66 ± 1.97# 0.001
ADULT 208.5 ± 8.55 14.43 ± 0.88* 205.65 ± 6.95 164.84 ± 11.33# 0.001
FORCE/WEIGHT (g/g) P14 1559.86 ± 292.25 834.2 ± 150.66* 1379.97± 404.56 1565.73± 367.12 0.018
P21 1021.27 ± 308.81 1474.97 ± 340.35* 1081.54± 86.26 1390.81± 306.78* 0.034
P28 1124.87 ± 156.98 571.16 ± 89.02* 1099.9 ± 152.2 1247.61± 53.81 0.006
ADULT 1460.03 ± 89.47 792.95 ± 138.6* 1407.11± 44.59 1341.69± 81.63 0.005
Values are expressed as Mean ± Standard deviation. Post-hoc multiple comparisons. *: different from control. #: different from crush. Level of significance was
a = 0.05.
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http://www.biomedcentral.com/1472-6793/12/5receptor antagonists is usually restricted, due to serious
side-effects [16,17]. This is the first time, to our best
knowledge, that DAP5 has been administered systemically.
Our goal was to evaluate both the drug effective dose and
its effect on locomotor behaviour and muscular properties.Methods
All procedures were performed in accordance with institu-
tional guidelines for the use and care of animals (86/609/
EEC) and the ‘Principles of Laboratory animal care’ (NIH
publication No 85–23, revised 1985) and were approved
by the Ethical Committee for animal experimentation of
the Medical School of Thessaloniki (2-3-2006). One
hundred seven Wistar rats of both sexes were used in this
study. The animals were provided with ad libitum access
to food and water and housed in standard cages in a 22°C
environment with a 12:12-h light–dark cycle. All efforts
were made to minimize the number of animals and their
suffering in the experiments.The pups (N= 80) were divided into four different
groups. Unoperated littermates either received DAP5
(N= 20) or remained as untreated controls (injected with
normal saline, N = 20). The third experimental group
(N= 20) comprised animals subjected to nerve crush and
treated with vehicle, whereas in the fourth group
(N= 20) were those animals with nerve crush, which
underwent treatment with DAP5. The study was
performed in four stages of postnatal development
(5 animals per age group), on postnatal days, 14, 21, 28
and during adulthood (2 months). The twenty seven
remaining rats participated in the titration study.Surgical procedures
Nerve crush
Adequate anesthesia was initiated and maintained by ether
inhalation. Surgery was performed under an operating
stereoscope. On the second postnatal day, a small incision
was performed in the posterior surface of the left mid-
Table 3 Soleus recordings-comparisons
AGE PROCEDURE
CRUSH DAP5 CRUSH-DAP5 P-VALUE
BODY WEIGHT P14 - - - 0.891
P21 - - - 0.064
P28 - - - 0.918
ADULT - - - 0.944
MUSCLE WEIGHT P14 - - - 0.257
P21 * - - 0.006
P28 * - # 0.001
ADULT * - # 0.001
TIME TO PEAK P14 - - - 0.630
P21 - * - 0.007
P28 * - - 0.048
ADULT - - - 0.744
HALF RELAXATION TIME P14 - - - 0.447
P21 - * - 0.009
P28 - - - 0.219
ADULT - - * 0.009
SINGLE TWITCH P14 * - - 0.005
P21 * - - 0.036
P28 * - # 0.002
ADULT * - # 0.002
TETANIC-100 P14 * - - 0.003
P21 * - - 0.023
P28 * # # 0.001
ADULT * - # 0.001
FATIGUE INDEX P14 * - - 0.009
P21 * - - 0.031
P28 - - - 0.063
ADULT * - - 0.010
Post-hoc multiple comparisons. The actual parameters are presented in the graphs. *: different from control. #: different from crush. Level of significance was
a = 0.05.
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http://www.biomedcentral.com/1472-6793/12/5thigh and the sciatic nerve was identified. The crush was
performed just proximal to its division to the peroneal and
tibial nerve. Attention was paid to avoid damage in the
nerve muscular surroundings. Crush was performed by
means of a fine pair of forceps which was tightly applied
for 30 seconds. Afterwards, the nerve was examined to en-
sure that the epineural sheath was intact, though translu-
cent. Bleeding was controlled with haemostatic cellulose
and the wounds were sutured with 6–0 silk threads. All
procedures were carried out by the same researcher. Three
hours after recovery from anaesthesia, peanut oil was ap-
plied to the wound (to avoid autophagia) and the pups
were returned to their mother.
In order to confirm the efficacy of the procedure, the
plantar and dorsiflexion reflexes, as well as the inability
of normal movement of the left hind limb, with animals
suspended from their tail, were assessed daily, for thefirst 7 days, as described elsewhere [1]. Only animals
with verified successful axotomy were included in our
study.Drug titration-administration
9 groups, each consisting of 3 animals were tested for
each dose. Under ether anesthesia, the animals were
injected subcutaneously at the interscapular region. The
injection was performed daily from P2 to P13. The dose
of 50 mg/kg was lethal 24 hours after treatment for all
animals. Escalating doses of 10, 20, 30, 40 mg/kg resulted
in no changes in rat growth, eating, water drinking, and
weight gaining. Doses of 45 mg/kg resulted lethal after
3 days. Doses ranging from 42-45 mg/kg resulted in
weight loss or were lethal. At the end, 40 mg/kg was
chosen as the treatment dose.
Table 4 Soleus tension recordings
SOLEUS
AGE PROCEDURE ANOVA ON THE RANKS
CONTROL CRUSH DAP5 CRUSH-DAP5 P-VALUE
WEIGHT-INDEX P14 0.03 ± 0. 0.03 ± 0. 0.03 ± 0.01 0.03 ± 0.01 0.364
P21 0.03 ± 0. 0.03 ± 0.* 0.03 ± 0.01 0.03 ± 0. 0.039
P28 0.04 ± 0. 0.02 ± 0.* 0.04 ± 0. 0.03 ± 0.# 0.001
ADULT 0.06 ± 0. 0.01 ± 0.* 0.06 ± 0. 0.04 ± 0.# 0.001
TETANIC-10 (g) P14 5.85 ± 1.35 1.65 ± 0.18* 5.06 ± 0.59 4.64 ± 0.67 0.005
P21 11.99 ± 0.68 9.88 ± 1.02* 13.84 ± 1.26# 13.3 ± 0.69# 0.005
P28 21.43 ± 2.06 10.92 ± 1.04* 20.1 ± 1.83 18.39 ± 2.03 0.004
ADULT 44.65 ± 0.81 9.15 ± 0.59* 41.72 ± 2.27# 40.77 ± 2.31# 0.002
TETANIC-20 (g) P14 6.78 ± 1.29 2.47 ± 0.44* 6.59 ± 0.75 5.45 ± 0.74 0.003
P21 16.94 ± 0.97 14.49 ± 0.74* 14.73 ± 1.51* 14.25 ± 0.9* 0.020
P28 35.76 ± 2.16 15.44 ± 0.6* 27.75 ± 2.08# 26.39 ± 2.57# 0.001
ADULT 54.1 ± 0.92 10.62 ± 0.89* 53.01 ± 1.65 49.61 ± 2.56# 0.002
TETANIC-40 (g) P14 8.46 ± 1.65 2.84 ± 0.3* 9.98 ± 0.73 8.05 ± 0.83 0.003
P21 24.27 ± 0.98 19.96 ± 2.02* 23.76 ± 1.39 21.71 ± 1.34# 0.007
P28 52.11 ± 2.51 17.63 ± 2.33* 32.62 ± 2.99# 29.19 ± 1.82# 0.001
ADULT 89.15 ± 7.15 14.16 ± 1.22* 91.78 ± 6.08 80.85 ± 3.04# 0.002
TETANIC-80 (g) P14 10.65 ± 1.32 3.48 ± 0.37* 11.91 ± 0.96 9.54 ± 0.65# 0.002
P21 33.56 ± 1.09 29.96 ± 1.7* 34.41 ± 2.25 32.47 ± 1.66 0.013
P28 69.89 ± 1.69 20.71 ± 2.92* 40.38 ± 2.1# 37.79 ± 1.83# 0.001
ADULT 130.03 ± 1.92 16.89 ± 0.98* 129.45 ± 2.36 121.16 ± 5.06# 0.002
FORCE/WEIGHT (g/g) P14 2037.05 ± 529.05 787.3 ± 156.* 2534.11 ± 461.66 1648.11 ± 392.76 0.003
P21 2046.25 ± 187.04 2370.38 ± 252.19* 1980.12 ± 357.46 2225.41 ± 213.59 0.131
P28 2710.54 ± 134.72 1272.12 ± 108.09 1421.89 ± 223.69# 1687.99 ± 175.58# 0.001
ADULT 1111.12 ± 25.62 787.93 ± 195.12* 1104.13 ± 20.91 1591.63 ± 127.07# 0.001
Values are expressed as Mean ± Standard deviation. Post-hoc multiple comparisons. *: different from control. #: different from crush. Level of significance was
a = 0.05.
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All animals were examined for the contractile properties
of two hind limb muscles, the extensor digitorum longus
(EDL) and soleus, which represent a fast contracting, easily
fatigable and a slow, fatigue resistant muscle, respectively.
Animals were anaesthetized with chloral hydrate (4.5%,
10 μl/g body weight, i.p.). The sciatic nerve was identified
and prepared proximal to its division. Indifferent to the
examined muscle branches of the sciatic nerve were cut.
The distal tendons were dissected from the surrounding
tissues, cut at their insertion at the bone and attached to a
strain gauge transducer (Dynamometer UFI, Devices) by a
short silk suture and the exposed parts of the muscles
were kept moist with warm (37°C) Krebs-Henseleit
solution. (NaCl 118.08 mM, NaHCO3 25 mM, glucose
5.55 mM and CaCl2 1.89 mM). Two pins were inserted in
the femoral and calcaneus condyles, thereby adjusting the
leg in a position of 90o flexion of the knee and the ankle
joints. Muscle length was appropriately adjusted in order
to produce maximal single twitch tension (optimal length),through a micromanipulator allowing motion on the 3
axes (Prior, England). The tension elicited by sciatic nerve
stimulation (Digitimer DS9A stimulator) was displayed on
the monitor using a specific Micro 1501 CED (Cambridge
Instruments, UK), after amplification by a DC transducer
amplifier (Neurolog NL 107).
Stimulus intensity was adjusted in order to elicit
maximal tension, using supramaximal (3–9 volts) square
pulses each of 0.5 msec duration. Time to peak (TTP) was
calculated by measuring the time taken to reach maximum
twitch tension. Time to half relaxation (1/2 RT) was
calculated as the time taken for peak twitch tension to
decrease to half its original value.
Tetanic contractions were then elicited by stimulat-
ing the nerve at 10, 20, 40, 80 and 100 Hz. All devices
during the tension recording procedure were con-
trolled by a pulse programmer (Digitimer D4030). The
fatigability of the muscles was tested by stimulating the
nerve at 40 Hz for 250 ms per second for 180 seconds.
During this process, the recorded muscle tension
Table 5 Locomotor tests
AGE PROCEDURE ANOVA ON THE RANKS
CONTROL CRUSH DAP5 CRUSH-DAP5 P-VALUE
Rotarod (sec) P14 264.20 ± 12.28 8.40 ± 2.70* 256.00 ± 12.02 19.00 ± 3.39 # 0.001
P21 289.80 ± 14.94 20.40 ± 6.50* 276.40 ± 16.02 51.40 ± 7.86# 0.001
P28 289.20 ± 11.80 37.20 ± 9.15* 290.60 ± 12.92 104.20 ± 9.98# 0.001
ADULT 285.80 ± 13.57 45.80 ± 7.98* 289.40 ± 15.03 229.80 ± 12.34# 0.001
Bridge 1 cm P14 1.20 ± 0.45 8.60 ± 0.55* 1.00 ± 0.71 4.20 ± 0.84# 0.001
P21 0.80 ± 0.84 7.40 ± 0.89* 0.60 ± 0.55 2.60 ± 1.52 0.003
P28 0.80 ± 0.84 7.20 ± 0.84* 1.00 ± 0.71 2.80 ± 0.45# 0.001
ADULT 0.80 ± 0.45 6.20 ± 1.10* 0.80 ± 0.45 3.00 ± 0.71# 0.001
Bridge 3 cm P14 0.80 ± 0.84 7.60 ± 0.89* 0.60 ± 0.55 2.80 ± 0.84# 0.001
P21 0.40 ± 0.89 7.00 ± 0.71* 0.40 ± 0.55 2.80 ± 0.84# 0.001
P28 0.60 ± 0.55 5.80 ± 1.30* 0.60 ± 0.89 2.20 ± 0.84# 0.002
ADULT 0.20 ± 0.45 5.00 ± 1.58* 0.60 ± 0.55 2.20 ± 0.84# 0.001
Bridge 5 cm P14 0.60 ± 0.55 6.20 ± 0.45* 0.00 ± 0.00 2.40 ± 0.55# 0.001
P21 0.40 ± 0.55 4.40 ± 1.14* 0.40 ± 0.55 1.60 ± 1.14 0.004
P28 0.40 ± 0.55 4.40 ± 1.14* 0.20 ± 0.45 2.00 ± 1.00# 0.001
ADULT 0.00 ± 0.00 2.80 ± 0.84* 0.20 ± 0.45 1.80 ± 0.84* 0.001
Gait 1 cm P14 2.80 ± 0.84 4.60 ± 0.89* 2.60 ± 1.14 3.40 ± 0.89 0.037
(errors) P21 2.40 ± 1.14 4.60 ± 0.55* 2.20 ± 1.48 3.00 ± 0.71 0.016
P28 2.80 ± 0.84 3.80 ± 0.84 2.40 ± 1.14 2.60 ± 0.89 0.149
ADULT 2.40 ± 1.14 4.00 ± 1.00 2.00 ± 1.58 2.00 ± 1.22 0.091
Gait 3 cm P14 2.40 ± 0.89 4.00 ± 0.71* 2.20 ± 0.84 2.80 ± 1.10 0.025
(errors) P21 1.80 ± 0.84 3.80 ± 0.84* 1.80 ± 1.30 1.80 ± 1.30 0.036
P28 1.80 ± 1.48 4.20 ± 0.84* 1.60 ± 0.89 2.00 ± 0.00 0.014
ADULT 1.80 ± 1.30 3.80 ± 1.30 1.60 ± 1.14 1.80 ± 1.30 0.094
Gait 5 cm P14 2.40 ± 1.52 3.40 ± 0.55 1.60 ± 1.14 3.00 ± 1.00 0.098
(errors) P21 1.40 ± 1.14 3.00 ± 0.71* 0.80 ± 0.84 1.40 ± 0.55 0.019
P28 1.80 ± 1.48 3.60 ± 0.89* 1.80 ± 0.45 1.20 ± 1.30 0.029
ADULT 1.20 ± 1.30 3.40 ± 1.52 1.20 ± 0.84 1.20 ± 0.84 0.089
Limb Rotation P14 13.40 ± 0.98 0.00 ± 0.00 13.18 ± 0.76 14.42 ± 0.89 0.194
P21 17.88 ± 0.44 21.24 ± 0.86* 17.90 ± 0.53 20.00 ± 0.83* 0.002
P28 18.62 ± 1.21 22.56 ± 0.79* 18.50 ± 0.86 22.12 ± 0.79* 0.002
ADULT 20.76 ± 1.87 27.28 ± 0.56* 20.62 ± 1.64 24.60 ± 0.72# 0.001
Stride Length (cm) P14 3.78 ± 0.53 0.00 ± 0.00 3.70 ± 0.29 2.30 ± 0.51* 0.010
P21 11.86 ± 0.56 9.94 ± 0.44* 12.02 ± 0.57 10.10 ± 0.70* 0.003
P28 15.78 ± 1.18 13.56 ± 0.41* 15.42 ± 1.19 13.76 ± 0.60* 0.006
ADULT 17.82 ± 0.68 13.14 ± 0.95* 18.02 ± 0.51 16.44 ± 0.54# 0.001
DBF(cm) P14 0.98 ± 0.18 0.00 ± 0.00 0.98 ± 0.22 0.64 ± 0.13* 0.027
P21 1.86 ± 0.18 1.30 ± 0.19* 2.02 ± 0.20 1.36 ± 0.13* 0.002
P28 2.70 ± 0.19 2.96 ± 0.11 2.78 ± 0.16 2.20 ± 0.14* 0.003
ADULT 3.34 ± 0.23 3.80 ± 0.19* 3.43 ± 0.19 2.92 ± 0.16# 0.003
Values are expressed as Mean ± Standard deviation. Post-hoc multiple comparisons. *: different from control. #: different from crush. Level of significance was
a = 0.05.
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http://www.biomedcentral.com/1472-6793/12/5gradually declined as the muscle fibers one by one
were losing their contraction ability. Then the fatigue
index was calculated as FI = (Initial tension-tensionafter 180 min)/Initial tension. After tension recordings
were completed, the animals were sacrificed and mus-
cles were excised and weighed.
Figure 1 Body Weight. No statistical significance was found among the experimental groups. Body weight increased with age in all groups.
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Movement behaviour was examined by performing 3
kinds of tests. All tests were performed at the same day
(P14, P21, P28, 2 months).
1. The Rotarod test in which a rodent was placed on a
rotating treadmill. The speed of rotation was
gradually increased at an accelerated speed of
4-40 rpm/min. The animals were placed at the
treadmill at which time the individual timers started
and the rodent’s ability to remain on the rotating rod
was recorded. The test lasted for a maximum of 10
minutes. When the animals fell off the treadmill the
timer stopped. The purpose of the Rotarod test is to
assess the rodent’s sensorimotor coordination
[18,19].
2. Bridging: rats are placed in three different (1, 3 and
5 cm wide) narrow wooden lanes of one meter long.
Two parameters were examined; the number of
errors in passing the bridge and the gait type
measured using a particular scale, ranging from 0 to
5 (corresponding to fluent gait with 2 stops, fluent
gait with many stops, fearful but with no stops,
fearful with stops, particularly difficult).3. Footprint analysis: The footprint analysis was
performed according to Jeroen et al and Alexander
Klein et al [20,21] to evaluate hindlimb walking
patterns. Briefly, the rats had to walk on strips of
paper through a walk away (1 m long, 6 cm wide).
Their hindpaws were dipped in blue fountain pen
ink. Three series of at least one stepping cycle per
side (four sequential steps) were performed per
experimental day. The parameters examined were:
stride length (distance between left and right
footprints), limb rotation (angle between a virtual
line through the third digit and the centre of the
palm and a virtual line parallel to the walking
direction) and distance between feet (distance
between feet of the left and right stepping cycle)
were analyzed.
Statistical analysis
Analysis was performed using SPSS 19.0 software for
Windows. Animals of the same age group were compared
among the different interventions and animals subjected
to the same procedure were compared among the different
developmental stages. Nonparametric tests were applied.
Figure 2 Muscle Weight. Muscle weight was reduced by crush, after P14 in EDL and after P21 in soleus (p< 0.01). DAP-5 increased muscle
weight, but not to the level of control animals.
Figure 3 EDL Force Generation. Bar chart showing the contractile force of the EDL muscle. Single twitch and maximum tetanic contraction at
100 Hz is depicted for all experimental groups in all ages. It is evident that crush animals developed significantly less tension than the controls
and DAP5 administration clearly improved muscle performance.
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Figure 4 Soleus Force Generation. Similar to Figure 1, showing the contractile force of soleus muscle.
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http://www.biomedcentral.com/1472-6793/12/5Kruskal – Wallis procedure was initially used in order
to detect differences between groups, following which
post-hoc pairwise comparisons were performed, by means
of a stepwise, step-down method. Criterion of statistical
significance was set at p< 0.05.Results
The results are presented in detail in Tables 1, 2, 3, 4, 5.A. Body-weight-muscle weight
Body weight did not differ between the experimental
groups (Figure 1). Muscle weight (Figure 2) and weight
index (muscle/body weight) in crush animals was
definitely reduced compared to controls (p< 0.01). This
reduction was already apparent by P14 in EDL, whereas in
soleus was evident after P21. Similarly, in crush animals
which received DAP5, the difference compared to controls
was evident after P14 in EDL and after P21 in soleus.
These animals also differed from animals with crush, with
differences becoming evident earlier, already at P14 in
EDL and at P21 in soleus. We have to note that during
normal development weight index changed (increased
in adulthood compared to P14, p< 0.01). Axotomy
progressively reduced the index, presumably due to muscleweight decrease. DAP-5 reversed this situation for both
muscles.B. Isometric tension recordings
Tension development: Treatment with DAP5 did not
alter the normal muscle properties, the only exception
being the soleus muscle in P21 and P28 animals, in
which the tetanic tensions were unexpectedly lower
(p< 0.01). The absence of muscle “side effects” was
consistent for both muscles in all age groups. In adult
rats, EDL single twitch in controls, DAP5–treated, crush
and crush +DAP5 treatment was 71.37 ± 3.64,
74.43 ± 3.30, 6.27 ± 0.67 and 61.24 ± 3.32gr, respectively
(values expressed as mean ± SD).When soleus was
considered, the respective values were 36.41 ± 1.71,
34.62 ± 1.56, 7.72 ± 0.93 and 31.76 ± 2.71gr. In all age
groups, animals with crush exhibited significantly less
tension than the controls in both muscles (p< 0.01).
Crush animals injected with DAP5 were definitely
improved as their tension recordings were significantly
higher than the crush ones without DAP5 in both
muscles (p< 0.01). This improvement however, did not
generally reach the level of control animals, nor those
with DAP5 injection (Figure 3–4).
Figure 5 EDL Time course of Contraction. Bar chart showing the evolution of the two parameters of the time course of contraction, among
the different experimental groups. TTP:time-to-peak and HRT:Half-relaxation-time. Immature EDL is a slow muscle, but progressively its contraction
is shortened in order to attain the fast profile of the adult animal. Crush disrupts this process and the muscle remains slow in all developmental
stages.
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http://www.biomedcentral.com/1472-6793/12/5Time course of contraction: The time course of soleus
contraction was not altered by axotomy and the muscle
remained slow-contracting in all developmental stages, in
all experimental groups. EDL, on the other hand, became
slower after the crush (p< 0.05). DAP5 administration
restored the contraction velocity, up to the level of
control animals (Figure 5–6).
Fatigue index: Following crush, EDL becomes fatigue
resistant after P21. In adult animals with crush the index
was 0.18 ± 0.03 vs 0.48± 0.03 in controls (p< 0.01). Soleus,
on the other hand, becomes less fatigue resistant
(0.2± 0.06 in controls vs 0.34± 0.09 in axotomized adults,
p< 0.01). DAP5 administration restored the profile in both
muscles (EDL: 0,48± 0.02, soleus: 0.24 ± 0.03, p< 0.01
compared to crush), up to the level of control animals (no
difference after P28)(Figure 7).
Specific tension: This parameter (tetanic tension
100 Hz/muscle weight) was reduced in crush animals in
both muscles (p< 0.01). DAP5 administration reversed
this effect.C. Movement behaviour
The results are presented in Table 5 and the performance
in rotarod test is shown in Figure 8. It should be noticed
that P14-crush animals were not able to perform the limb
rotation, stride length and DBF, presumably due to their
young age to participate in these tests.
Injection of DAP5 had no impact in animal locomotion,
as there was no significant difference compared to
controls, in any age group, in any parameter studied.
Among the various experimental groups, crush animals
had definitely lower motor scores than the controls
(p< 0.05). These differences remained throughout all
ages, apart from adults, in which the gaits exhibited no
significant changes. DAP5 administration in axotomized
animals improved motor behaviour (p< 0.05 compared to
axotomized). For limb rotation, stride length and DBF, the
difference became evident after P28. This improvement,
however, reached the level of neither the controls
(p< 0.05), nor those with intact nerve and DAP5 treat-
ment (p< 0.05).
Figure 6 Soleus Time course of Contraction. Bar chart showing the evolution of the two parameters of the time course of contraction, among
the different experimental groups. TTP:time-to-peak and HRT:Half-relaxation-time. Soleus remains a slow muscle in all developmental stages, in all
procedures.
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http://www.biomedcentral.com/1472-6793/12/5Concerning the evolution of locomotor behaviour, the
animal performance in the gaits and the bridges did not
exhibit any discernible difference, as the animals grew
older. On the other hand, the rotarod, the limb rotation,
the stride length and the DBF provided a more robust
index of the differentiation of the animals’ locomotion,
with significant differences between the age groups
(p< 0.05).Discussion
It is well established that peripheral nerve crush injury,
during early postnatal development, results in significant
loss of motor neurons and extensive muscle atrophy [1,9].
The mechanism of cell death involves, on the one hand,
the activation of several apoptotic pathways [22] and on
the other hand the necrotic cell death, probably caused by
glutamate-mediated excitotoxicity [2,6]. The differential
response between mature and immature motoneurons
following injury is attributed to the quantity of glutamate
receptors on the cell membrane [23,24].Administration of an NMDA or AMPA/Kainate receptor
antagonist within this critical period of development is
thought to reverse the neurotoxic effects of axotomy and
result in increased survival of motoneurons [2,5,7,25,26].
Unfortunately, the protective effects for many of these
factors are only transient, lasting 2–3 weeks [27].
Dizocilpine malate (MK-801), an NMDA antagonist, has
been used in animal models in vivo with success, in order
to prevent motoneuron death after axotomy. It was badly
tolerated by rats, however, due to side effects and high
mortality [2,25]. Furthermore, magnesium, which is known
to act as a voltage-dependent blocker of the N-methyl-D-
aspartate (NMDA) channel, by coupling with the specific
Mg2+ site within the pore of the ion channel [28,29], was
found to inhibit the death of ventral horn motoneurons
and to restore the alteration in contractile properties
provoked by axotomy [1].
In the present study we assessed the contractile
properties and the movement behaviour in rats of
different age groups, following neonatal sciatic nerve
crush and administration of DAP5. This is a selective
Figure 7 Fatigue index. Bar chart showing the fatigue index for both muscles (A.EDL B.Soleus) in all developmental stages for all procedures.
Fatigue index normally decreases by age. Crush renders EDL fatigue resistant after P21, while soleus becomes more fatiguable. DAP5 restored the
profile in both muscles.
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http://www.biomedcentral.com/1472-6793/12/5NMDA receptor antagonist that competitively inhibits
the ligand (glutamate) binding site of NMDA receptors.
DAP5 is generally very fast acting as indicated by in vitro
preparations, and can block NMDA receptor action at a
reasonably small concentration [30]. Our hypothesis was
that, by delivering an agent with a direct action on the
NMDA receptor, we would be able to achieve a more
profound effect, than the one observed with the indirect
action of magnesium. A drawback in our study is that
axotomized hindlimbs were not compared with the ones
of the opposite side (right), but with those of control
animals, thus rendering our observations more
vulnerable to interanimal differences. We chose that
design, however, to achieve a correlation with the
behavioural tests, which necessarily had to entail a
control group of animals. Moreover, body weight did not
differ among the experimental groups and consequently
the differences in tension recordings may be directly
ascribed to the muscle changes.
According to our knowledge, this is the first time that
DAP5was administered in vivo. Systematic administration
of DAP5 has been discouraged by other researchers, due
to poor cerebrospinal fluid (CSF) absorption and probable
toxic features [17]. By initially following titration trials, we
did not observe any side effects. In all age groups, no
significant difference was found between control animals
and those that the agent was administered, in both
contractile properties and behavioural tests. These resultsallowed us to conclude that a safe and effective therapeutic
profile is evident for the aforementioned drug, at least for
the parameters studied.
Apart from reducing the number of surviving moto-
neurons, axotomy in the early postnatal period alters the
contractile properties of limb muscles, as well [3]. Our
results are in accordance with our previous work [1], as
well as other researchers [2], showing that axotomy
severely impairs tension development by the muscle. The
main feature in this study is that DAP5 resulted in the
recovery of the contractile properties of both muscles,
up to the level of control animals, thus fully eliminating
the debilitating effect of axotomy. We assume that the
direct action of the agent on the NMDA receptor
accounts for the improved results.
Concerning the time evolution of contraction, we
reconfirmed that immature (P14) muscles are not yet
differentiated into fast- or slow-contracting ones and that
fast contracting muscles are more severely affected by
axotomy [1,3,31]. In the early developmental stages,
contraction in both muscles is rather prolonged, with a
high fatigue index. In control animals, EDL attains its
normal features by adulthood, in the case of axotomy,
however, the muscle becomes slow and fatigue resistant.
At this point, there was a differentiation concerning our
previous work, as DAP5 succeeded in recuperating in a
greater degree the original features of the muscle. In
agreement with the majority of researchers, it was of no
Figure 8 Rotarod test. Bar chart showing the duration that the animals achieved on the rotarod. Crush resulted in a definite reduction in time
and DAP-5 increased the capacity.
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http://www.biomedcentral.com/1472-6793/12/5surprise that soleus did not present any alteration in its
time course of contraction, as its contractile properties
are not significantly altered throughout early postnatal
life. Concerning fatigability, normally soleus is converted
progressively into a fatigue resistant muscle. This process
is halted, in case of axotomy and is partially reversed by
DAP5 administration. We also have to point out that
differences were statistically significant in most param-
eters among the various age groups (within the same
experimental group), reflecting the fact that all animals
underwent the natural course of contractile properties
maturation (force augmentation during development).
In order to evaluate the locomotion, a series of tests was
applied, which comprised the rotarod, as well as passing
along bridges of different width and footprint analysis.
The results were in full correlation with the isometric
recordings. Rats with axotomy exhibited overt changes
in their locomotor behaviour, compared with controls.
Treatment with DAP5 improved movement, although the
difference with controls was still discernible. Improvement
in locomotor behaviour, following DAP5 administration,however, was not as impressive as the one observed in
tension recordings. Axotomy provokes a serious sensori-
motor disruption, early in development, and coordination
of the limbs during walking does not entirely rely on
the reinforcement of individual muscles. Adaptive
mechanisms are activated to compensate for the lack of
function; the injured rat exerts a notifying effort to use
the crushed leg and eventually succeeds in walking,
nevertheless, with uncontestable difference with respect to
the non-injured one. In addition, it seems that some tests
are more specific in delineating subtle differences between
the different groups. The rotarod and the footprint
analysis turned out to evaluate locomotor behaviour in a
more efficient way, than the observation and the grading
of the gait.
The lack of side-effects seems rather unexpected in our
study, compared to what has been described in the
literature [32]. The NMDA receptor contributes to
plasticity, neuronal differentiation and synaptogenesis in
the developing nervous system [33]. NMDA antagonists
are notorious for causing a multitude of behavioural
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http://www.biomedcentral.com/1472-6793/12/5sequelae. The disfunction of this receptor is frequently
considered to contribute to the pathophysiology of
schizophrenia, depression, anxiety and, indeed, these
agents are usually implemented in the research of several
psychotic states [34]. Moreover, MK-801, one of the most
extensively studied drugs in this category, is known to
induce long term behavioural disturbances, when
administered in neonatal rats [35]. One could argue that
our locomotor models may not be so sensitive to detect
this kind of behavioural defect. Furthermore, despite
sharing nominally common mechanisms of action and
often presumed biological equivalence, the NMDA
antagonists present very diverse effects [36]. Most
antagonists used in animal studies, such as MK-801, act
via an uncompetitive antagonism, whereas DAP5 utilizes a
competitive mode of action. It might be that, this mode of
action, in association with the affinity of the receptor,
should provide an effective combination which varies
among the different substances and explains the magni-
tude of primary actions as well as the side effects.Conclusions
Our results show that contractile properties and
locomotor behaviour of animals are severely affected by
axotomy, with a differential impact on fast contracting
muscles. Administration of DAP5 reverses these devastat-
ing effects. To our knowledge, this is the first time that the
systematic action of DAP5 is studied and the absence of
apparent side-effects is very important, although further
research is certainly required, in order to detect direct
or indirect, local or systemic actions, which were not
identified in our study.
The implications of such findings are apparent. By
possessing a relatively safe pharmacologic profile and the
encouraging results described above, this agent could be
explored in a variety of animal models dealing with
excitotoxic cell death.
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